The development of new technologies now allow scientists to investigate the molecular basis
and clinical manifestations of monoclonal B cell lymphocytosis (MBL), chronic lymphocytic
leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom
macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these methods in
a natural history study can clarify processes involved in disease progression and possibly
lead to the discovery or validation of treatment targets.
- Study the biology and natural history of MBL/CLL/SLL in patients prior to the time
when their disease requires treatment and the biology of LPL/WM and SMZL.
- Characterize clinical, biologic and molecular events of disease stability and
progression of patients enrolled on this protocol.
- Diagnosis of MBL/CLL/SLL/LPL/WM/SMZL
- Age greater than or equal to 18 years.
- Patients with CLL/SLL must not have received previous cytotoxic, monoclonal
antibody, or kinase inhibitor therapy.
- Patients with LPL/WM or SMZL can have prior therapy.
- ECOG performance status of 0-2.
- Patients are typically followed every 6 to 24 months in the clinic and have blood
drawn. When required patients may undergo additional testing that may include bone
marrow biopsy and aspiration, blood drawing, lymph node biopsy, x-ray studies,
positron emission tomography and CT and MRI scans. Some of these tests may be
required to monitor CLL/SLL, LPL/WM, and SMZL patients. Other tests, such as bone
marrow biopsy and aspiration, lymph node biopsy, may not be clinically indicated,
but patients may be asked to undergo these procedures for research purposes)
- Clinical information is collected and stored in a central databank.
- Patients whose cancer requires treatment will be taken off the study and treatment
options will be discussed with them. If no NIH treatment protocols are available to
them, they will be returned to the care of their local physician.